Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report

Yue Zhang,1 Rushan Xia1,2 1Department of Dermatology, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, People’s Republic of China; 2Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of ChinaCor...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhang Y, Xia R
Format: Article
Language:English
Published: Dove Medical Press 2025-06-01
Series:Clinical, Cosmetic and Investigational Dermatology
Subjects:
Online Access:https://www.dovepress.com/refractory-segmental-hyaline-vasculitis-treated-with-janus-kinase-inhi-peer-reviewed-fulltext-article-CCID
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850157372967747584
author Zhang Y
Xia R
author_facet Zhang Y
Xia R
author_sort Zhang Y
collection DOAJ
description Yue Zhang,1 Rushan Xia1,2 1Department of Dermatology, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, People’s Republic of China; 2Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of ChinaCorrespondence: Rushan Xia, Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of China, Tel +8618861843704, Email wxeyxrs@163.comAbstract: This article reports a 59-year-old female patient who was diagnosed with segmental hyaline vasculitis and treated with tofacitinib for 2 months. In this case, multiple dark purplish-red spots were seen on both lower limbs, which did not fade with pressure. Flaky dark red spots, petechiae, ulcers, and necrosis were seen on the ankles. Histopathological manifestations were consistent with segmental hyaline vasculitis. The lesions subsided after the patient was treated with oral tofacitinib 5 mg twice daily for 1 month.Keywords: cutaneous vasculitis, segmental hyaline vasculitis, tofacitinib
format Article
id doaj-art-90ff23baedbf458dbcf0437ccccc370d
institution OA Journals
issn 1178-7015
language English
publishDate 2025-06-01
publisher Dove Medical Press
record_format Article
series Clinical, Cosmetic and Investigational Dermatology
spelling doaj-art-90ff23baedbf458dbcf0437ccccc370d2025-08-20T02:24:13ZengDove Medical PressClinical, Cosmetic and Investigational Dermatology1178-70152025-06-01Volume 18Issue 114531457103824Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case ReportZhang Y0Xia R1DermatologyDermatologyYue Zhang,1 Rushan Xia1,2 1Department of Dermatology, The Affiliated Wuxi No. 2 People’s Hospital of Nanjing Medical University, Wuxi, Jiangsu, People’s Republic of China; 2Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of ChinaCorrespondence: Rushan Xia, Department of Dermatology, The Affiliated Central Hospital of Jiangnan University, Wuxi, Jiangsu, People’s Republic of China, Tel +8618861843704, Email wxeyxrs@163.comAbstract: This article reports a 59-year-old female patient who was diagnosed with segmental hyaline vasculitis and treated with tofacitinib for 2 months. In this case, multiple dark purplish-red spots were seen on both lower limbs, which did not fade with pressure. Flaky dark red spots, petechiae, ulcers, and necrosis were seen on the ankles. Histopathological manifestations were consistent with segmental hyaline vasculitis. The lesions subsided after the patient was treated with oral tofacitinib 5 mg twice daily for 1 month.Keywords: cutaneous vasculitis, segmental hyaline vasculitis, tofacitinibhttps://www.dovepress.com/refractory-segmental-hyaline-vasculitis-treated-with-janus-kinase-inhi-peer-reviewed-fulltext-article-CCIDcutaneous vasculitissegmental hyaline vasculitistofacitinib
spellingShingle Zhang Y
Xia R
Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
Clinical, Cosmetic and Investigational Dermatology
cutaneous vasculitis
segmental hyaline vasculitis
tofacitinib
title Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
title_full Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
title_fullStr Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
title_full_unstemmed Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
title_short Refractory Segmental Hyaline Vasculitis Treated with Janus Kinase Inhibitor Tofacitinib: A Case Report
title_sort refractory segmental hyaline vasculitis treated with janus kinase inhibitor tofacitinib a case report
topic cutaneous vasculitis
segmental hyaline vasculitis
tofacitinib
url https://www.dovepress.com/refractory-segmental-hyaline-vasculitis-treated-with-janus-kinase-inhi-peer-reviewed-fulltext-article-CCID
work_keys_str_mv AT zhangy refractorysegmentalhyalinevasculitistreatedwithjanuskinaseinhibitortofacitinibacasereport
AT xiar refractorysegmentalhyalinevasculitistreatedwithjanuskinaseinhibitortofacitinibacasereport